产品端聚焦核心赛道+多元布局，研发管线持续推进。公司以"片仔癀"为 主产品，拥有锭剂及胶囊剂两种剂型，具有相同的成分及功能主治。持续做 大做强茵胆平肝胶囊、复方片仔癀含片、川贝清肺糖浆、复方片仔癀软膏等 系列产品。此外，公司拓展美妆赛道表现亮眼，明星产品皇后牌珍珠膏 25H1 销售额同比+60%。在新品研发上，今年 10 月公司 1.1 类中药创新药温胆片 III 期临床完成首例受试者入组，适应症为轻、中度广泛性焦虑障碍。 持续发力渠道建设。截至 2025 年 6 月，在覆盖全国近 400 家片仔癀国药堂 的基础上，公司增加片仔癀国药堂、国医馆的设立；加强自营线上线下平台 的精细化服务，聚焦拓展主流连锁渠道；通过全资子公司福建片仔癀健康科 技有限公司，与益丰等多家头部知名连锁药房建立了全品类战略合作伙伴关 系，实现终端门店覆盖超过 10 万家。 投资建议：我们预计公司 2025/2026/2027 年 EPS 分别为 4.04/4.40/4.82 元。公司核心产品片仔癀系列具备稀缺属性，维持 "增持"评级。 风险提示：消费复苏不及预期风险，原材料成本波动的风险。 公司点评 | 片仔癀 业绩短期承压，期待毛利率 ...

Investment Rating - The report maintains an "Accumulate" rating for the company [1][10]. Core Views - The company has shown a revenue growth of 6.02% year-on-year for the first three quarters of 2025, with a total revenue of 216.28 billion yuan and a net profit attributable to shareholders of 53.22 billion yuan, reflecting a 10.54% increase [10]. - The introduction of new product categories has been a highlight, with revenue from soy sauce, oyster sauce, seasoning sauces, and other condiments increasing by 7.9%, 5.9%, 9.6%, and 13.4% respectively [10]. - The gross margin for Q3 2025 improved to 39.63%, up by 3.02 percentage points year-on-year, primarily due to the decline in prices of key raw materials such as soybeans and sugar [10]. Financial Summary - The company’s total market capitalization is 224.827 billion yuan, with a total share capital of 5,852 million shares [3]. - The net asset per share is 6.76 yuan, with a price-to-book ratio of 5.7 [4]. - The projected earnings per share (EPS) for 2025-2027 are 1.20, 1.35, and 1.51 yuan, respectively, indicating a year-on-year growth of 11%, 12%, and 12% [10][11]. Revenue and Profit Forecast - The company’s revenue is expected to grow from 24.559 billion yuan in 2023 to 35.652 billion yuan by 2027, with a compound annual growth rate (CAGR) of approximately 11.4% [9][11]. - The net profit attributable to shareholders is projected to increase from 5.627 billion yuan in 2023 to 8.860 billion yuan in 2027, reflecting a steady growth trajectory [9][11].

Core Viewpoint - RLX Technology (RLX.US) experienced a significant stock increase of over 9%, reaching $2.542, following the release of its Q3 earnings report, which showed robust revenue and profit performance, exceeding market expectations [1] Financial Performance - For Q3, RLX Technology reported revenue of $158.6 million, representing a year-over-year increase of 47.1%, and surpassing market expectations by approximately $18.1 million [1] - The Non-GAAP earnings per ADS for Q3 were $0.031, aligning with market expectations [1] Profitability - The company's gross margin improved from 27.2% in the same period last year to 31.2% in Q3, indicating effective cost control and product mix optimization [1] Financial Position - As of September 30, the company had a total of RMB 15.351 billion (approximately $2.156 billion) in cash, restricted cash, short-term and long-term bank deposits, and investment securities, providing a solid financial foundation for future business expansion [1]

Core Viewpoint - CICC maintains a "outperform" rating for Uni-President China (00220), while lowering the profit forecast for 2025 and 2026 by 3% and 6% to 2.23 billion and 2.47 billion yuan respectively, with a target price of 11.5 HKD, indicating a potential upside of 28.5% based on 20/18 times P/E for 2025/2026 [1] Group 1: Financial Performance - In Q3 2025, the company's net profit reached 726 million yuan, representing an 8.4% year-on-year increase, aligning with market expectations [1] - The estimated Q3 revenue remained flat year-on-year, with food business showing moderate growth while beverage business faced slight declines due to intensified competition in the market [2] - The gross margin for the first nine months of 2025 showed a slight improvement year-on-year, attributed to lower raw material prices and increased capacity utilization [3] Group 2: Business Strategy and Market Conditions - The beverage segment experienced a decline in October compared to Q3, primarily due to external factors such as delivery subsidies and industry destocking, but the company maintains a stable pricing strategy and aims to explore high-potential outlets for future growth [4] - The company introduced new products in Q3, including 100% NFC blueberry juice and lemon ginger apple juice, to enhance its product portfolio [2] - The company is focusing on optimizing expense inputs and brand building, leading to a decrease in expense ratio year-on-year [3]

Core Viewpoint - The company's gross margin is declining primarily due to rising raw material prices, which are on an overall upward trend [1] Group 1: Financial Performance - The company's gross margin is experiencing a downward trend [1] - The Thai subsidiary is currently in a ramp-up phase and operating at a loss, contributing to the decline in gross margin [1] Group 2: Strategic Response - The company plans to adjust its product structure and focus on developing high value-added products to gradually improve the declining gross margin situation [1]

Core Viewpoint - The company expects an improvement in gross margin by Q2 2025, primarily due to an increased proportion of high-margin products in its product mix [1] Summary by Categories Financial Performance - The company anticipates that the overall price of its products has stabilized, leading to an expected improvement in gross margin levels in the second half of the year compared to the first half [1]

Core Insights - The company reported a revenue fluctuation in Q3 2025, with total revenue for the first three quarters reaching 18.68 billion yuan, a year-on-year increase of 6.67% [1] - Net profit attributable to shareholders decreased by 14.34% to 2.435 billion yuan, while the non-recurring net profit fell by 10.83% to 2.500 billion yuan [1] - Q3 single-quarter revenue, net profit, and non-recurring net profit were 6.019 billion yuan, 765 million yuan, and 816 million yuan, respectively, showing year-on-year changes of -0.34%, -20.73%, and -14.83% [1] Revenue and Sales Performance - The company sold 168 million pairs of sports shoes in the first three quarters of 2025, a year-on-year increase of 3.04%, with an increase in average selling price (ASP) [1] - In Q3, sales volume decreased by 3.6% to 5.3 million pairs due to short-term order adjustments from some old customers [1] - The company is accelerating new customer expansion and optimizing customer structure, with three out of four new production factories expected to achieve profitability in Q3 2025 [1] Profitability and Cost Management - The gross margin for the first three quarters was 21.96%, a year-on-year decrease of 5.85 percentage points, but Q3 gross margin improved by 1.11 percentage points compared to Q2 [2] - The company has implemented cost control measures, with selling and administrative expense ratios at 0.27% and 2.75%, respectively, showing year-on-year changes of -0.08 and -2.54 percentage points [2] - Inventory turnover days decreased to 58 days, down by 6 days year-on-year, indicating improved turnover efficiency [2] Investment Outlook - The company is in a rapid capacity expansion phase, with new factory efficiency expected to improve over time [2] - Following the adjustment of old customer orders, a recovery in orders is anticipated in 2026 [2] - EPS estimates for 2025, 2026, and 2027 have been revised down to 2.84, 3.37, and 3.91 yuan, respectively, with corresponding PE valuations of 20, 17, and 15 times [2]

Core Insights - The company achieved a total revenue of 1.356 billion yuan in the first three quarters of 2025, representing a year-on-year growth of 12.05% [1] - The net profit attributable to shareholders reached 201 million yuan, with a year-on-year increase of 3.51% [1] - The company reported a non-recurring net profit of 175 million yuan, showing a year-on-year growth of 19.40% [1] Revenue and Profit Performance - In Q3 2025, the company generated a revenue of 522 million yuan, marking a year-on-year increase of 16.74% [1] - The net profit attributable to shareholders for Q3 was 70 million yuan, reflecting a year-on-year decrease of 16.07% [1] - The non-recurring net profit for Q3 was 74 million yuan, with a year-on-year growth of 25.53% [1] Store Performance and Product Segments - The company saw a net increase of 249 stores, bringing the total to 5,934, with revenue from franchise/owned stores/group meal channels growing by 17.7%/42.3%/11.6% respectively [1] - The company’s single-store performance showed improvement, with product revenue in Q3 2025 for dumplings, fillings, and purchased food increasing by 1.3%/27.7%/26.5% year-on-year [1] Margin and Cost Management - The gross margin improved by 2.9 percentage points to 29.7% in Q3 2025, attributed to better cost control and reduced raw material costs [2] - Selling and administrative expense ratios decreased by 0.4 and 1.8 percentage points to 3.6% and 6.9% respectively, leading to an increase in gross profit margin by 3.3 percentage points to 26.1% [2] - The non-recurring net profit margin rose by 1.0 percentage point to 14.2% in Q3 2025 [2] New Product Offerings - The introduction of a new dining model featuring soup dumplings is expected to enhance single-store efficiency, catering to consumer demand for diverse meal options [2]

Core Viewpoint - The company reported a revenue of 18.68 billion yuan for the first three quarters of 2025, a year-on-year increase of 6.67%, but the net profit attributable to shareholders decreased by 14.34% to 2.435 billion yuan, indicating challenges in profitability despite revenue growth [1]. Revenue and Profit Analysis - For Q3 2025, the company achieved a revenue of 6.019 billion yuan, a slight decline of 0.34% year-on-year, with net profit attributable to shareholders dropping by 20.73% to 765 million yuan [1][2]. Order and Sales Performance - The company sold 16.8 million pairs of sports shoes in the first three quarters of 2025, reflecting a year-on-year growth of 3.04%. However, Q3 saw a decline in volume by approximately 3.7%, while the average selling price (ASP) increased by about 3.5% [2]. Gross Margin and Cost Management - The gross margin for Q3 2025 was approximately 22.2%, down 4.8 percentage points year-on-year, primarily due to the initial efficiency ramp-up of new factories. However, there was a sequential improvement of 1.1 percentage points, indicating progress in production efficiency [3]. - Management and sales expense ratios decreased by 3.0 and 0.1 percentage points to 2.7% and 0.13%, respectively, with a significant reduction in management fees due to lower performance-related compensation [3]. Production Capacity and Inventory Management - The company is making steady progress in expanding production capacity, with three out of four new sports shoe factories expected to start production in 2024 already achieving profitability during the reporting period. This suggests that the negative impact on profits from new capacity is gradually diminishing [4]. - As of the end of Q3 2025, the company's inventory balance was 3.159 billion yuan, remaining stable since the beginning of the year, with inventory turnover days maintained at a healthy level of approximately 58 days [4]. Profit Forecast and Investment Recommendation - The profit forecast has been adjusted due to slight operational pressures on some brand clients, with expected net profits for 2025-2027 revised to 3.457 billion, 3.982 billion, and 4.735 billion yuan, respectively. The company is still rated as a "buy" due to its strong ties with leading international brands and steady capacity growth [5].

Investment Rating - The report assigns a rating of "Outperform" for the company, indicating an expected total return over the next 12-18 months that exceeds the return of its relevant broad market benchmark [20]. Core Insights - The company reported a slight year-on-year decline in revenue for the first nine months of 2025, with total operating revenue of RMB 4.50 billion, down 5.4% year-on-year, and a significant drop in net profit attributable to owners, which fell by 73.2% to RMB 170 million [2][8]. - The gross profit margin for the first nine months was 21.9%, contracting by 8.3 percentage points year-on-year, but the gross margin for 3Q25 showed a sequential improvement to 24.5% [2][9]. - The company has set a clear revenue growth target of 10%-15% for the new fiscal year, with specific growth targets for sunflower seeds and nuts [4][11]. Financial Performance Summary - For the first nine months of 2025, the company achieved total operating revenue of RMB 4.50 billion, a decrease of 5.4% year-on-year, and a net profit attributable to owners of RMB 170 million, down 73.2% year-on-year [2][8]. - The gross profit margin for the first nine months was 21.9%, down 8.3 percentage points year-on-year, while the gross margin for 3Q25 was 24.5%, showing a sequential increase [2][9]. - The effective tax rate for the first nine months was 26.6%, up from 21.2% in the prior year period [2][8]. Revenue Structure and Product Performance - In 3Q25, the revenue from the sunflower seed business declined due to proactive control of sales, while the nut business grew by approximately 10%-20%, benefiting from strong performance during the Mid-Autumn Festival [3][9]. - The management indicated that the gross margin for nuts decreased by over 10 percentage points year-on-year, primarily due to rising prices of key raw materials [3][9]. Raw Material Costs and Future Outlook - Procurement prices for sunflower seeds have decreased compared to the same period in 2024, which is expected to benefit gross margins in 4Q25 and FY2026 [4][10]. - The company plans to enhance long-term control over core raw materials by expanding contract farming [10]. New Fiscal Year Plan - The company aims for sales revenue growth of 10%-15% for the period from July 2025 to June 2026, with specific targets for sunflower seeds and nuts [4][11]. - New product initiatives include a focus on konjac, with a target scale of RMB 50-100 million [4][11]. Channel Development - The traditional Key Account (KA) channel's contribution to sales has decreased from 40% to 35%, while the Snack Discount channel has seen rapid growth [5][12]. - Membership stores have performed well, with significant sales growth in the Hema channel [5][12].